Arıcı, S. Et Al. 2020. The clinical importance of fibroblast growth factor 23 on advanced non-small cell lung cancer patients without druggable alterations in genes as EGFR or ALK or ROS1 Fibroblast growth factor 23. Eurasian Journal of Medical Investigation , vol.4, no.3 , 365-369.

Arıcı, S., Çekin, R., Seçmeler, Ş., Atçı, M. M., Ocak, B., Sakin, A., ... Cihan, Ş.(2020). The clinical importance of fibroblast growth factor 23 on advanced non-small cell lung cancer patients without druggable alterations in genes as EGFR or ALK or ROS1 Fibroblast growth factor 23. Eurasian Journal of Medical Investigation , vol.4, no.3, 365-369.

Arıcı, Serdar Et Al. "The clinical importance of fibroblast growth factor 23 on advanced non-small cell lung cancer patients without druggable alterations in genes as EGFR or ALK or ROS1 Fibroblast growth factor 23," Eurasian Journal of Medical Investigation , vol.4, no.3, 365-369, 2020

Arıcı, Serdar Et Al. "The clinical importance of fibroblast growth factor 23 on advanced non-small cell lung cancer patients without druggable alterations in genes as EGFR or ALK or ROS1 Fibroblast growth factor 23." Eurasian Journal of Medical Investigation , vol.4, no.3, pp.365-369, 2020

Arıcı, S. Et Al. (2020) . "The clinical importance of fibroblast growth factor 23 on advanced non-small cell lung cancer patients without druggable alterations in genes as EGFR or ALK or ROS1 Fibroblast growth factor 23." Eurasian Journal of Medical Investigation , vol.4, no.3, pp.365-369.

@article{article, author={Serdar Arıcı Et Al. }, title={The clinical importance of fibroblast growth factor 23 on advanced non-small cell lung cancer patients without druggable alterations in genes as EGFR or ALK or ROS1 Fibroblast growth factor 23}, journal={Eurasian Journal of Medical Investigation}, year=2020, pages={365-369} }